

# Anat Naschitz

[anat@9xc.co](mailto:anat@9xc.co)

[LinkedIn](#)



Anat Naschitz is an investor and a creator – of funds and companies.

Currently she is **co-founder and CEO of 9xchange**, a biopharma marketplace, aiming to liberate untapped but valuable assets/technologies through a curated, electively anonymous system encompassing quality investors, pharma and biotech.

Previously (2009-2023), Anat **co-founded and co-led OrbiMed** Israel, raising 2 funds with \$529m under management. OrbiMed is a preeminent global healthcare investment firm with ~\$20 billion under management across public and private asset classes.

Anat has served on the boards of public and private biotech, digital health and medical device companies, some of which she either founded or nurtured from an early stage. During her **27+ years** in the healthcare space, Anat has worked with companies of all sizes, including major pharmaceutical companies on the one hand and nascent ones on the other. She has operated globally and remains geographically agnostic.

Anat is a doer, energizer, connector, coach, harmonizer, alongside acting as the responsible adult vis a vis multiple stakeholders. In short – a leader. She has broad and deep networks and is generous with her time and access.

**Examples for boards** on which Anat has served include **89bio (Nasdaq:ETNB)**, a biotech company she co-founded as a pharma spinout and helped take public 18 months later; **Tytocare**, a telemedicine device platform in which she invested early and saw through notable success; ForSight **Vision 6**, developing an Accommodating IntraOcular Lens under a Strategic agreement; **Azura**, who recently published strong phase 2b data for a novel therapeutic for MGD, the overwhelming cause for dry eye disease; and **MDCIone**, commercializing novel analytics and synthetic technology which enable immediate querying and sharing of healthcare data.

Previously Anat was an Associate Partner with **McKinsey** in London, where she led strategy and M&A work for senior management of the world's preeminent pharmaceutical and biotechnology companies. Among other accomplishments, Anat led pharmaceutical spinout work resulting in the creation of European biotech companies, including BioVitrum, which merged into **SOBI (STO:SOBI)**, currently valued at ~\$7bn.

Post McKinsey Anat joined **Apax** Partners, where she focused on life sciences investments.

She earned her M.B.A. at **INSEAD** and her LL.B. at Tel Aviv University.

Anat speaks multiple languages, paints, sings, writes and nurtures her family.